Skip to main content
SpringerLink
Log in

Early-Stage Breast Cancer in Older Adults

  • Living reference work entry
  • First Online:
Geriatric Oncology

  • 110 Accesses

Abstract

Breast cancer is the most common cancer afflicting women worldwide. Its incidence peaks around 70, while mortality increases greatly after 75 years old. Given the competing risks on mortality with multimorbidities, geriatric assessment is a leitmotiv and is considered as the mandatory and non-opposable strategy to use for personalizing treatment. This is especially true for strategies used in early-stage breast cancer since benefits are expected to come with long follow-up.

Therefore treatment choice needs careful assessment of the benefit/risk balance and guidance according to a general health status assessment, in order to avoid jeopardizing functional status and quality of life.

This chapter will highlight the unmet clinical needs, future opportunities and adjusted strategies for local treatments (surgery and radiotherapy), and systemic treatments (chemotherapy, endocrine therapy, and anti-HER2 treatment) in the older patients with early-stage breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Association of Breast Surgery Multidisciplinary Consensus Meeting on the further management of the malignant axillary node. In Association of Breast Surgery Consensus Statement. 2015. London.

    Google Scholar 

  • Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet. 1896;2:104–7.

    Article  Google Scholar 

  • Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13:e148–60.

    Article  Google Scholar 

  • Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG task force. Cancer Treat Rev. 2016;43:19–26. https://doi.org/10.1016/j.ctrv.2015.11.009.. Epub 2015 Dec 15

    Article  CAS  PubMed  Google Scholar 

  • Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 2013;49:2294–302.

    Article  CAS  Google Scholar 

  • Brain E, Caillet P, de Glas N, Biganzoli L, Cheng K, Lago LD, Wildiers H. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. J Geriatr Oncol. pii: S1879-4068(18)30479-X. https://doi.org/10.1016/j.jgo.2019.06.004. [Epub ahead of print] Review.

  • Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. Herceptin adjuvant (HERA) trial study team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;S0140–6736(16):32616–2.

    Google Scholar 

  • Chakrabarti J, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol. 2011;78(3):260–4.

    Article  CAS  Google Scholar 

  • Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367–77.

    Article  CAS  Google Scholar 

  • Cheung KL, et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies--a large series from a single Centre. Crit Rev Oncol Hematol. 2008;67(3):263–7.

    Article  CAS  Google Scholar 

  • Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–92.. Epub 2007 Jan 2

    Article  CAS  Google Scholar 

  • Coates AS, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast Cancer 2015. Ann Oncol. 2015;26(8):1533–46.

    Article  CAS  Google Scholar 

  • Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–60.

    Article  Google Scholar 

  • Coussy F, Mir O, Bourbouloux E et al. ASTER 70S or optimal adjuvant treatment for women over 70 with luminal breast cancer: a GERICO/UNICANCER phase III trial. J Geriatric Oncol. 2016. (SIOG 2016 annual meeting Abs 1362).

    Google Scholar 

  • Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12. https://doi.org/10.1093/annonc/mdx308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.

    Article  CAS  Google Scholar 

  • Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.

    Article  Google Scholar 

  • Earl H, Hiller L, Vallier AL, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. ASCO 2018 abstract 506.

    Google Scholar 

  • Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24(18):2757–64.

    Article  Google Scholar 

  • FAST Trialists group. First results of the randomised UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93–100.

    Article  Google Scholar 

  • Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6.

    Article  Google Scholar 

  • Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.

    Article  CAS  Google Scholar 

  • Hind D, et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1:CD004272.

    Google Scholar 

  • Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7. https://doi.org/10.1200/JCO.2012.45.2615. Epub 2013 May 20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hurria A, Magnuson A, Gross CP, Tew WP, Klepin HD, Wildes TM, Muss HB, Dotan E, Freedman R, O’Connor T, Dale W, Cohen HJ, Katheria V, Arsenyan A, Levi A, Kim H, Sun CL. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study. SABCS. General Session 6. 2018. https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_1273&terms=.

  • Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist. 2014;19(10):1076–83. https://doi.org/10.1634/theoncologist.2014-0184. Epub 2014 Aug 20

    Article  PubMed  PubMed Central  Google Scholar 

  • Johnston SJ, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012;23(9):2296–300.

    Article  CAS  Google Scholar 

  • Jones S, Holmes FA, O’Shaugnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27:1177–83.

    Article  CAS  Google Scholar 

  • Kendal WS. Dying with cancer: the influence of age, comorbidity, and cancer site. Cancer. 2008;112(6):1354–62. https://doi.org/10.1002/cncr.23315.

    Article  PubMed  Google Scholar 

  • Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R, Bollet MA, Salmon RJ, Fourquet A, Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):76–81.

    Article  Google Scholar 

  • Kramar A, Bachelot T, Madrange N, et al. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. Ann Oncol. 2014;25:153–1570.

    Article  Google Scholar 

  • Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014;25(11):2134–46.

    Article  CAS  Google Scholar 

  • Lyman GH, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.

    Article  Google Scholar 

  • Meattini I, Saieva C, Marrazzo L, Di Brina L, Pallotta S, Mangoni M, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat. 2015;153:539–47.

    Article  CAS  Google Scholar 

  • Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer – a comparison of randomised controlled trial and cohort study findings. Eur J Surg Oncol. 2014;40(6):676–84.

    Article  CAS  Google Scholar 

  • Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L, Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.

    Article  CAS  Google Scholar 

  • Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65. https://doi.org/10.1056/NEJMoa0810266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2):124–32. https://doi.org/10.1016/j.critrevonc.2008.01.013. Epub 2008 Mar 28

    Article  PubMed  PubMed Central  Google Scholar 

  • Robertson JF, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.

    Article  CAS  Google Scholar 

  • Sawaki M, Saito T, Baba S et al. Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial (RESPECT) ASCO 2018; abstract 510.

    Google Scholar 

  • Schonberg MA1, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010;28(12):2038–45. https://doi.org/10.1200/JCO.2009.25.9796. Epub 2010 Mar 22.

    Article  Google Scholar 

  • Slamon DJ, Eiermann W, Robert MJ, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients. 2015 San Antonio Breast Cancer Symposium Abstract S5–04.

    Google Scholar 

  • Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.

    Article  CAS  Google Scholar 

  • Syed BM, et al. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single Centre. Br J Cancer. 2011;104(9):1393–400.

    Article  CAS  Google Scholar 

  • Syed BM, et al. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. Br J Cancer. 2013;108(5):1042–51.

    Article  CAS  Google Scholar 

  • Syed BM, et al. Tamoxifen versus anastrozole as primary endocrine therapy in older women with early operable primary breast cancer. J Clin Oncol. 2014;32(15 Suppl):e11533.

    Article  Google Scholar 

  • Tolaney SM, Barry WT, Guo H, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(Suppl 15):511.. ASCO. Abstract 511

    Article  Google Scholar 

  • Vaz-Luiz I, Keating NL, Lin NU, et al. Duration of toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32:927–34.

    Article  Google Scholar 

  • von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31.

    Article  Google Scholar 

  • Yancik R, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–92.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Nottingham, Nottingham, UK

    Kwok-Leung Cheung

  2. Radiation Oncology Unit – Oncology Department – AOU Careggi, University of Florence, Florence, Italy

    Lorenzo Livi

  3. Department of Medical Oncology, Institut Curie, Saint-Cloud, France

    Etienne Brain

Authors
  1. Kwok-Leung Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Livi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Etienne Brain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Etienne Brain .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL, USA

    Martine Extermann

Section Editor information

  1. Department of Medical Oncology, Institut Curie, Saint-Cloud, France

    Etienne Brain

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Cheung, KL., Livi, L., Brain, E. (2019). Early-Stage Breast Cancer in Older Adults. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-44870-1_33-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44870-1_33-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44870-1

  • Online ISBN: 978-3-319-44870-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation